Header
For Healthcare Professionals

JARDIANCE® is now approved for CKD protection and indicated1:

check mark image for HF
To reduce the risk of sustained decline in eGFR (only for patients with eGFR 
30-90 mL/min/1.73 m2), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
check mark image for HF

To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
check mark image for HF
To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
check mark image for HF
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin has Grade 1A recommendation for treatment of CKD, as demonstrated in the EMPA-KIDNEY study-population2
Empagliflozin has Grade 1A recommendation, as a first-line drug for treatment of patients with T2DM and CKD3

  • CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; T2DM=type 2 diabetes mellitus.

  1. API dated 19th Jul 2024 (Based on JARDIANCE® approved prescribing information dated 18th Jul 2024).

  2. UK Kidney association; 2023 Update: Summary of changes to Recommendations available at: https://guidelines.ukkidney.org/2023-update/ Accessed on: 27th June 2024.

  3. KDIGO Clinical Practice Guideline, 2024; Available at: https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf Accessed on: 27th June 2024